appear in the yolk sac and the fetal liver without affecting differentiation. 4 However, additional genetic aberrations are needed to induce leukemia, as individuals with a germline splicing mutation of GATA1 only show a macrocytic anemia and neutropenia, but no leukemia.
In the past years it has become increasingly apparent that dysregulated transcriptional control is a key event in the pathogenesis of numerous examples of hematologic malignancy. So far, multiple recurrent chromosomal anomalies and gene rearrangements have been identified for most subsets of acute myeloid leukemia (AML). In a number of current pathogenesis models for AML and myelodysplastic syndromes (MDS) the recruitment of histone deacetylases (HDACs) is a crucial event and therefore the basis for innovative epigenetic treatment strategies. 1 HDACs comprise an increasing number of proteins, which may be divided into four major families on the basis of their sequence homology with their ancestor proteins in yeast: RPD3 (class I HDACs (HDAC1, 2, 3 and 8)), HDA1 (class II HDACs (4, 5, 6, 7, 9 and 10)), SIR2 (class III HDACs (sirtuins 1-7)) and HDAC11 (class IV HDAC). They play a key role in the regulation of transcription, cell cycle, differentiation and apoptosis and their dysregulation is involved in tumorigenesis. [2] [3] [4] HDACs have also been suggested to mediate the function of oncogenic translocation products in specific forms of leukemia 5 , in which chromosomal translocations create fusion proteins that block terminal differentiation of hematopoietic cells by recruiting multi-protein corepressor complexes, including class I HDACs, to target promoters.
3,6-8 HDAC3 (5q31) and HDAC9 (7p21) are of special interest because of their gene loci in chromosomal regions, which have been described to be frequently altered preferentially in MDS and secondary AML. [9] [10] [11] A single nucleotide polymorphism (SNP) is a difference between chromosomes in the base present at a particular site in the DNA sequence, which naturally occur within a population, presenting the most common type (90%) of genetic variation in humans. 12 SNPs are used for identification of inherited cancer susceptibility genes and there are great hopes that increasing knowledge of an individual's SNP genotype will provide additional information in the assessment of disease susceptibility and individualized treatment modalities. SNPs as disease markers are now the great hope of genetics.
In this context, it was the aim of our study to carry out SNP studies for HDACs that seem to play a decisive role in the pathogenesis of AML and which are typically located within chromosomal regions that are frequently altered in MDS and AML patients.
To identify SNPs in class I HDACs and HDAC9 we performed in silico analyses on three SNP databases; (1) the NIH Database of Single Nucleotide Polymorphisms (dbSNP), Bethesda (MD), National Center for Biotechnology Information, National Library of Medicine (dbSNP Build 125), 13 (2) HapMap 14 and (3) Applied Biosystems 15 ), which led to the identification of a total of 899 putative, validated and nonvalidated SNPs, which were divided into 883 intronic and 16 exonic, coding SNPs (cSNPs), whereupon the latter were further divided into six synonymous and 10 nonsynonymous SNPs.
The in silico analysis of the HapMap database revealed no validated nonsynonymous cSNPs in the analyzed HDACs. Via
Letters to the Editor the dbSNP (rs-no.) and AB.-SNP-Database 10 nonsynonymous cSNPs could be identified (Table 1) . Nine cSNPs were identified via the dbSNP; HDAC1: rs11541185, rs11541183, rs16834961; HDAC2: rs17852888, rs1042903, rs1126963, rs1042902 and HDAC3: rs11546659 and rs467744. Two cSNPs were identified via the AB.-SNP-database; C_25629707_10 and C_982763_20, whereas the latter is identical with the cSNP rs467744. For HDAC8 and HDAC9 no nonsynonymous cSNPs were found.
The allelic discrimination was focused on the identified 10 coding, nonsynonymous SNPs, as they were most likely to affect gene function, since they went along with changes in the aminoacid sequence. For allelic discrimination we used TaqMan-PCRbased allele specific SNP Assays (Applied Biosystems, Darmstadt, Germany). With each SNP Assay 279 DNA probes from healthy donors and AML patients (Table 2) were screened, respectively. DNA samples and the diagnostic data of 279 AML patients at diagnosis included in the AML96 trial (NCT 00180102) 16 of the DSIL (Deutsche Studieninitiative Leukämie) were examined. The study was approved by the local ethics committee and each patient gave written informed consent.
Genomic DNA from the healthy donors was extracted from 5 ml peripheral blood (EDTA blood) by standard methods. DNA quantification was carried out on a Nanodrop ND-1000 Spectrophotometer (Peqlab Biotechnologie GmbH, Erlangen, Germany).
To confirm, if we can detect a SNP, appointing the proper frequency, via SNP Assays of Applied Biosystems, we analyzed DNA of healthy donors with a validated cSNP of a class III HDAC, identified via dbSNP and HapMap (rs11246020), exhibiting all possible three genotypes (homozygote allele 1: A/A ¼ 0.05, homozygote allele 2: G/G ¼ 0.72 and heterozygote: A/G ¼ 0.23). Our allelic discrimination showed all three genotypes and approved the allele frequencies of HapMap (data not shown).
The results of the allelic discrimination of the identified putative cSNPs of 279 healthy donors compared to 279 AML patients ( Figure 1 ) showed no allelic differences either within the population of healthy Caucasian individuals or in AML patients.
The importance of the identification and validation of nonsynonymous SNPs in HDACs also becomes apparent by paying regard to the fact that nonsynonymous SNPs can cause alterations in protein function, like increased or decreased activity or alterations in binding capability of substrates and protein complexes, which, in the case of HDACs, can cause epigenetic changes, that can be reversed by inhibitors or activators of HDACs, respectively. When this occurs, normal patterns of gene expression, hematopoietic differentiation, and apoptosis may be restored and disease response obtained.
Taken together, our results indicate that the identified cSNPs were in fact false positives, since allelic differences failed to be confirmed both within the population of healthy Caucasian individuals and also in AML patients. Hence these data suggest that a correlation between class I HDAC SNPs and an expected susceptibility to AML does not exist. Abbreviation: FAB, French-American-British. For two female and three male patients the diagnosis of primary or secondary AML was not specified, the others were classified into the characteristic subgroups.
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The fact, that despite the putative cSNPs that we have identified, numerous nonsynonymous SNPs that are frequently identified by many authors will never show any relation to diseases does not affect the promise of SNP analysis to be a powerful new tool for the discovery and improvement of our understanding for hereditary factors involved in health and disease. Therefore, further analyses of gene SNPs within 'critical regions' will be needed in order to identify a reliable susceptibility marker for leukemias and other types of cancer. 
Similar to solid tumors, acute leukemia growth induces neo-vascularization (angiogenesis) within the bone marrow (BM) microenvironment. Several studies have shown that acute myeloid leukemia (AML) cells release angiogenic growth factors such as vascular endothelial growth factor (VEGF) within the BM. In turn, AML growth and expansion involves the activation of BM vessels, resulting in a paracrine stimulation of leukemia, similar to what is seen in solid neoplasms. In addition, we and others have shown that subsets of acute leukemias also express VEGF receptors; in these cases, autocrine stimulation of leukemia cells by VEGF may result in proliferation, migration and resistance to chemotherapy. [1] [2] [3] Therefore, exposure of the BM microenvironment to increased VEGF levels may in fact contribute toward leukemia expansion via paracrine or autocrine stimulation of subsets of leukemia cells.
More recently, we have shown that acute lymphocytic leukemia expansion and the onset of extramedullary disease involved migration of leukemia cells, within the BM microenvironment and into the peripheral circulation. 4 This migration was induced at least partly due to VEGF/PLGF (placental derived growth factor) stimulation of leukemia cells within the BM. However, the molecular mechanisms involved in this migration were not characterized, and are the subject of the present study.
Although several reports have implicated the cell cytoskeleton, namely actin and tubulin, in the migration of different cell types, few have studied its importance in VEGF-induced leukemia cell migration.
VEGF or PLGF stimulation of AML cell lines resulted in a significant increase in cell migration over control (nonstimulated) cells (Figure 1a) . PLGF (which binds only FLT-1 (fms-related tyrosine kinase 1)) was more potent at inducing AML migration than VEGF itself ( Figure 1a , the difference between PLGF and VEGF stimulation versus control condition, Po0.05); accordingly, the migratory effects of VEGF were blocked by the use of an FLT-1 tyrosine kinase inhibitor (IR1; IC 50 ¼ 2.0 mM) and also by the small interfering RNA designed to block FLT-1 expression (Figure 1a) . In contrast, PLGF/VEGF addition produced a modest effect on AML cell proliferation/ survival (see Supplementary Figure 1A) .
Next, we characterized the mechanisms whereby PLGF induced leukemia migration. PLGF stimulation of HEL and HL60 cell lines in vitro resulted in the formation of FLT-1 membrane protrusions (Figure 1b) . Similar results regarding FLT-1 localization after PLGF stimulation were obtained by studying two BM samples obtained from AML patients (M3 and M4). In addition, we verified whether PLGF stimulation induced FLT-1 tyrosine phosphorylation (Figure 1c) . Importantly, coincubation with the FLT-1 inhibitor (IR1) blocked PLGF-induced protrusion formation (Supplementary Figure 1B) and FLT-1 phosphorylation (Figure 1c) . Phalloidin staining (which identifies polymerized actin) indicated that these PLGF-induced membrane protrusions consisted of polymerized actin bundles which co-stained with FLT-1 (Supplementary Figure 2A) . PLGF treatment clearly resulted in the formation of phalloidin-stained membrane protrusions (Supplementary Figure 2B ; Po0.01 between PLGF and control conditions).
Regarding the activation of downstream signalling pathways, PLGF induced extracellular signal-regulated kinase 1/2 (ERK1/2) and P38 phosphorylation, but did not induce Akt phosphorylation (Figure 2a ). In addition, we also investigated the involvement of Rho-GTPases in modulating the effects of PLGF. As shown in Figure 2b , PLGF stimulation resulted in Rac-1 and RhoA induction, whereas Cdc42 was not affected. Concerning the activation of p21-activated kinase (PAK), an enzyme known to be activated by other receptor tyrosine kinases, there was an increase in PAK-1 phosphorylation following PLGF stimulation (Figure 2c ). We also observed that cofilin, a small actin-binding protein known to promote the regeneration of actin filaments, is activated by PLGF stimulation (Figure 2c) .
As we had previously implicated Hsp90 as being part of protein:protein complexes that modulate some of the intracellular signals following VEGF stimulation of leukemia cells, 5 we investigated whether PLGF signalling also involved Hsp90. As shown in Figure 2d , PLGF promoted the recruitment of Hsp90 and its binding to actin and FLT-1; these interactions were blocked by co-incubation with the FLT-1 inhibitor IR1 (Figure 2d ). In contrast, the microtubular cytoskeleton had a modest interaction with FLT-1 or Hsp90 (Supplementary Figure 3) .
Taken together, the data obtained suggest that PLGF stimulation of AML cells results in ERK1/2 and P38 phosphorylation, Rac1, RhoA, PAK1 and cofilin activation, together with the formation of protein:protein complexes at the cell membrane, which involve actin, FLT-1 and Hsp90. Importantly, these results were obtained in AML cell lines and also in primary leukemia samples (not shown).
Next, we investigated the formation and possible involvement of lipid domains such as caveolae or lipid rafts in modulating the effects of PLGF on AML cells. The caveolin scaffolding domain (amino acids 82-101) of caveolin-1 recognizes characteristic peptide sequences named as caveolin-binding domains within a variety of signalling molecules and several growth factor receptors. 6 We carried out a SWISSPROT database search and found that human FLT-1 sequence has one caveolin-1
